Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia
Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. This beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with APC in sepsis has been associate...
Saved in:
| Published in: | Thrombosis and haemostasis Vol. 106; no. 6; p. 1189 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Germany
01.12.2011
|
| Subjects: | |
| ISSN: | 0340-6245, 2567-689X, 2567-689X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. This beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with APC in sepsis has been associated with a better therapeutic response as compared to later treatment. In a mouse model it was recently confirmed that recombinant murine (rm-)APC decreases coagulation activation and improves survival in pneumococcal pneumonia; however, APC did not impact on the inflammatory response. The aim of this study was to determine the effect of APC treatment instigated early in infection on activation of coagulation and inflammation after induction of pneumococcal pneumonia. Mice were infected intranasally with viable S. pneumoniae . Mice were treated with rm-APC (125 μg) or vehicle intraperitoneally 12 hours after infection and were sacrificed after 20 hours, after which blood and organs were harvested for determination of bacterial outgrowth, coagulation activation and inflammatory markers. In this early treatment model, rm-APC treatment inhibited pulmonary and systemic activation of coagulation as reflected by lower levels of thrombin-antithrombin complexes and D-dimer. Moreover, rm-APC reduced the levels of a large number of cytokines and chemokines in the lung. When administered early in pneumococcal pneumonia, rm-APC inhibits systemic and pulmonary activation of coagulation and moreover exerts various anti-inflammatory effects in the lung. |
|---|---|
| AbstractList | Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. This beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with APC in sepsis has been associated with a better therapeutic response as compared to later treatment. In a mouse model it was recently confirmed that recombinant murine (rm-)APC decreases coagulation activation and improves survival in pneumococcal pneumonia; however, APC did not impact on the inflammatory response. The aim of this study was to determine the effect of APC treatment instigated early in infection on activation of coagulation and inflammation after induction of pneumococcal pneumonia. Mice were infected intranasally with viable S. pneumoniae . Mice were treated with rm-APC (125 μg) or vehicle intraperitoneally 12 hours after infection and were sacrificed after 20 hours, after which blood and organs were harvested for determination of bacterial outgrowth, coagulation activation and inflammatory markers. In this early treatment model, rm-APC treatment inhibited pulmonary and systemic activation of coagulation as reflected by lower levels of thrombin-antithrombin complexes and D-dimer. Moreover, rm-APC reduced the levels of a large number of cytokines and chemokines in the lung. When administered early in pneumococcal pneumonia, rm-APC inhibits systemic and pulmonary activation of coagulation and moreover exerts various anti-inflammatory effects in the lung. Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. This beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with APC in sepsis has been associated with a better therapeutic response as compared to later treatment. In a mouse model it was recently confirmed that recombinant murine (rm-)APC decreases coagulation activation and improves survival in pneumococcal pneumonia; however, APC did not impact on the inflammatory response. The aim of this study was to determine the effect of APC treatment instigated early in infection on activation of coagulation and inflammation after induction of pneumococcal pneumonia. Mice were infected intranasally with viable S. pneumoniae . Mice were treated with rm-APC (125 μg) or vehicle intraperitoneally 12 hours after infection and were sacrificed after 20 hours, after which blood and organs were harvested for determination of bacterial outgrowth, coagulation activation and inflammatory markers. In this early treatment model, rm-APC treatment inhibited pulmonary and systemic activation of coagulation as reflected by lower levels of thrombin-antithrombin complexes and D-dimer. Moreover, rm-APC reduced the levels of a large number of cytokines and chemokines in the lung. When administered early in pneumococcal pneumonia, rm-APC inhibits systemic and pulmonary activation of coagulation and moreover exerts various anti-inflammatory effects in the lung.Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. This beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with APC in sepsis has been associated with a better therapeutic response as compared to later treatment. In a mouse model it was recently confirmed that recombinant murine (rm-)APC decreases coagulation activation and improves survival in pneumococcal pneumonia; however, APC did not impact on the inflammatory response. The aim of this study was to determine the effect of APC treatment instigated early in infection on activation of coagulation and inflammation after induction of pneumococcal pneumonia. Mice were infected intranasally with viable S. pneumoniae . Mice were treated with rm-APC (125 μg) or vehicle intraperitoneally 12 hours after infection and were sacrificed after 20 hours, after which blood and organs were harvested for determination of bacterial outgrowth, coagulation activation and inflammatory markers. In this early treatment model, rm-APC treatment inhibited pulmonary and systemic activation of coagulation as reflected by lower levels of thrombin-antithrombin complexes and D-dimer. Moreover, rm-APC reduced the levels of a large number of cytokines and chemokines in the lung. When administered early in pneumococcal pneumonia, rm-APC inhibits systemic and pulmonary activation of coagulation and moreover exerts various anti-inflammatory effects in the lung. |
| Author | Schouten, Marcel Levi, Marcel Roelofs, Joris J T H van der Poll, Tom Grinnell, Brian W van 't Veer, Cornelis Gerlitz, Bruce |
| Author_xml | – sequence: 1 givenname: Marcel surname: Schouten fullname: Schouten, Marcel email: m.schouten@amc.uva.nl organization: Center for Experimental and Molecular Medicine, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room G2-130, 1105 AZ Amsterdam, The Netherlands. m.schouten@amc.uva.nl – sequence: 2 givenname: Cornelis surname: van 't Veer fullname: van 't Veer, Cornelis – sequence: 3 givenname: Joris J T H surname: Roelofs fullname: Roelofs, Joris J T H – sequence: 4 givenname: Bruce surname: Gerlitz fullname: Gerlitz, Bruce – sequence: 5 givenname: Brian W surname: Grinnell fullname: Grinnell, Brian W – sequence: 6 givenname: Marcel surname: Levi fullname: Levi, Marcel – sequence: 7 givenname: Tom surname: van der Poll fullname: van der Poll, Tom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21901240$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kM1LxDAUxIMoun7cPEtunqov2SRtjrL4BYIgCt6W1-StRppkbVNlj_7nFlxPwww_BmYO2W7KiRg7FXAhhIHL5zshKjAVqHmzw2ZSm7oyjX3dZTOYK6iMVPqAHQ7DB4Awyup9diCFBSEVzNjPE7kc25AwFY6uhC8s5Pm6z4VC4guOpVAap3DgLuPb2OU1lvcNx-R5SKsOY8QScuLf75Q4-hhSGAr1Uwlh320miMexD4n4OtEYs8vOYbc1KeAx21thN9DJVo_Yy8318-Kueni8vV9cPVSuFk2ptFxJa9u5bMlILa22rW6oRi1BeQsKvbNt3bbG1155QhRawEoh1giyqaU8Yud_vdO2z5GGsoxhcNR1mCiPw9JCA6AbaSbybEuObSS_XPchYr9Z_r8mfwGH0XNO |
| CitedBy_id | crossref_primary_10_1097_CCM_0b013e31828a4316 crossref_primary_10_1160_TH11_12_0833 crossref_primary_10_1586_14787210_2014_928198 crossref_primary_10_1016_j_thromres_2013_01_016 crossref_primary_10_1111_j_1538_7836_2012_04622_x crossref_primary_10_1160_TH13_02_0099 crossref_primary_10_1016_j_ijcard_2013_11_029 crossref_primary_10_1007_s11908_013_0358_9 crossref_primary_10_1160_TH13_11_0967 crossref_primary_10_1111_jth_12646 crossref_primary_10_1160_TH11_07_0510 crossref_primary_10_1160_TH13_10_0859 crossref_primary_10_1186_s12879_014_0559_3 crossref_primary_10_1134_S0006297917070033 crossref_primary_10_1160_TH11_11_0766 crossref_primary_10_1111_hae_13463 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1160/TH11-06-0438 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2567-689X |
| ExternalDocumentID | 21901240 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 0VX 123 1KJ 4.4 53G 5RE AAQQT ABJNI ABOCM ACGFO ACGFS ACNUY AENEX AFFNX AGCGI AHRSK ALMA_UNASSIGNED_HOLDINGS BR6 C45 CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P H13 J5H NPM OVD P2P RTC RTE SJN TEORI X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c718t-52f299b32be6252959b58e7a5204d904adc9b7bb6d7d4deaa1510f4aa7a028722 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000298719100023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-6245 2567-689X |
| IngestDate | Thu Jul 10 21:57:56 EDT 2025 Mon Jul 21 06:06:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c718t-52f299b32be6252959b58e7a5204d904adc9b7bb6d7d4deaa1510f4aa7a028722 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21901240 |
| PQID | 908005826 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_908005826 pubmed_primary_21901240 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-12-01 |
| PublicationDateYYYYMMDD | 2011-12-01 |
| PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationTitleAlternate | Thromb Haemost |
| PublicationYear | 2011 |
| SSID | ssj0016495 |
| Score | 2.1315527 |
| Snippet | Recombinant human activated protein C (APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1189 |
| SubjectTerms | Animals Anti-Inflammatory Agents - administration & dosage Antithrombin III - metabolism Biomarkers - metabolism Blood Coagulation - drug effects Cytokines - metabolism Disease Models, Animal Down-Regulation Fibrin Fibrinogen Degradation Products - metabolism Humans Lung - drug effects Lung - metabolism Lung - pathology Male Mice Mice, Inbred C57BL Peptide Hydrolases - metabolism Pneumonia, Pneumococcal - blood Pneumonia, Pneumococcal - immunology Protein C - administration & dosage Recombinant Proteins - administration & dosage Streptococcus pneumoniae - growth & development Streptococcus pneumoniae - immunology Streptococcus pneumoniae - pathogenicity |
| Title | Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21901240 https://www.proquest.com/docview/908005826 |
| Volume | 106 |
| WOSCitedRecordID | wos000298719100023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ07T8MwEMctoAwsPMSrvHQDa9Q0iZN4Qqii6kLVoUjZIjt2oBJ1Cm2KGPnm3DkpG2JgiRQpliL777uf7fMdY7d0mCREyb1-X_tehITvpVoqL5IheRhKMlW4YhPJeJxmmZi0sTnLNqxyYxOdodZVQXvkPUFowxGG7xZvHhWNosPVtoLGNuuESDIk6iRzNeg4Tv84Fdkm1D32e9NRv4nxicL0d5x0bmV48M8fOmT7LU_CfSOAI7Zl7DH7okXlXLkgF6CbC2skSg0uJ8PMwgAoqaatCTOhqORz_VpRZeJPkFYDSg5V0txohI8XY0G2CXaprCcYyoiMH8Gc9ukNLKyp5xWaVRzs9sXO5Al7Gj5MByOvrbXgFeidVrgeLdExqTBQBldEgeBC8dQkkgd-pIUfSV0IlSgV60RH2kiJpOCXkZSJREJJguCU7djKmnMGOtahULrgfol4EHNRogRSbGc04okquww2HZqjlumAQlpT1cv8p0u77KwZlHzR5NzIAwIXpI-Lvxtfsj238etiTq5Yp8R5bK7ZbrFezZbvN04j-BxPHr8B3yXLGQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recombinant+activated+protein+C+attenuates+coagulopathy+and+inflammation+when+administered+early+in+murine+pneumococcal+pneumonia&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Schouten%2C+Marcel&rft.au=van+%27t+Veer%2C+Cornelis&rft.au=Roelofs%2C+Joris+J+T+H&rft.au=Gerlitz%2C+Bruce&rft.date=2011-12-01&rft.issn=0340-6245&rft.volume=106&rft.issue=6&rft.spage=1189&rft_id=info:doi/10.1160%2FTH11-06-0438&rft_id=info%3Apmid%2F21901240&rft_id=info%3Apmid%2F21901240&rft.externalDocID=21901240 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon |